At Aurigene Pharmaceutical Services, we offer solutions encompassing a diverse set of synthetic chemistry challenges, while being able to make a difference leveraging our chemical inventory and analytical capacity. Our scientists are able to tackle complex problems in all areas of drug discovery. In addition to this, our scientists are well-versed in all aspects of modern synthetic chemistry The team is well-versed in the synthesis of NCEs at all scales, from milligram quantity for a simple primary screening for biochemical, cellular, and ADME assays followed by gram scale for efficacy and toxicology studies.
With a combination of synthetic chemistry expertise backed with advanced technology and setup, we offer solutions encompassing a diverse set of synthetic chemistry solutions. We supply multi-gram quantities of high purity compounds to support our client’s research needs across the discovery cycle.
As one of the leading CDMO, our expertise in synthetic chemistry services includes:
Heterocyclic Chemistry
Synthesis of O, N, S, and P heterocyclics and fused-ring analogues.
Transition Metal-mediates Reactions
C-C, C-N, C-O, C-P, C-S, C-B, C-Sn, and C-Si bond-forming reactions, C-H activations, etc.
Difficult-to-handle and Sensitive Reagents
Including all kinds of metal-based pyrophoric reagents like lithium, magnesium, and zincs, toxic reagents like metallic cyanides, and metal carbonyls etc.
Handling of Gaseous Reagents
Experienced in reactions involving gases like H2, Cl2, O2, CO, CO2, SO3 etc. – in addition to rarer reactions like ozonolysis – even at larger scales.
Specialized Synthetic Needs
- Fluorinations
- Cyclopropanations
- Deuteration & Isotopic labeling
- Labelled and tagged compounds
Multigram-quantity
Scales ranging from milligram to kilogram, through a very flexible array of business models including FTE, FFS, or Hybrid models.
Niche fields of interest
Photoredox reaction, decarboxylative C-C bond-forming reactions, metal-mediated C-H activation/amination of carbonyl compounds, electro organic reactions etc.
Protein degraders
Chemistry of PROTACs and molecular glues PROTACs, including the synthetic of various non-traditional CRBN, VHL, MDM2 and cIAP1-based E3-Ligase ligands. Ligation strategies involving C-C, C-O, and C-N spacers range from a chain length of two to twenty as well as novel rigid-type linkers for improving physicochemical properties. We have a proven track record of generating small libraries of partial PROTACs and a readily available stock of linkers.
Why Aurigene Pharmaceutical Services?
Expertise in handling novel & complex chemistries
Multi-step synthesis
Expertise in bioorganic chemistry including carbohydrates, steroids, peptides, lipids and nucleosides
Reference compounds and scaffold synthesis
Advanced technology and platforms (Oligonucleotides, PROTACs, Lipids)
Scales ranging from milligram to kilogram
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Pharmaceutical Analytical Services
Polymorph Screening
ADME/DMPK Services
Drug Formulation Services
In vivo Pharmacology
Medicinal Chemistry
Microbiology Testing
Peptide Synthesis
Development & Kilo Lab
Toxicology Studies
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
OCTOBER 01, 2024
PROTACs: Research for a life without cancer
PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Case study: Tackling CYP 2C9 inhibition challenges
The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...
Read More
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2022
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market